Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?
Mené sur 39 patients atteints d'une tumeur hématologique réfractaire ou récidivante, cet essai de phase I/Ib évalue les caractéristiques pharmacocinétiques, l'activité antitumorale et la dose maximale tolérée d'un composé appelé BP1001, un inhibiteur de Grb2 dispensé d'abord en monothérapie, puis en combinaison avec de faibles doses de cytarabine
Acute myeloid leukaemia is an aggressive disease with a poor prognosis. Whereas intensive combination chemotherapy represents a standard of care for fit patients, the most appropriate treatment for patients who are either unfit with multiple comorbidities or with relapsed or refractory disease remains debatable. Patients not considered as candidates for intensive chemotherapy because of old age, poor performance status, or disease-related adverse prognostic risk factors have an especially poor prognosis, with a median survival of less than 10 months
The Lancet Haematology , commentaire, 2017